MindImmune Therapeutics, Inc. Employee Directory
Biotechnology ResearchRhode Island, United States11-50 Employees
MindImmune is a pre-clinical stage company focused on neuro-inflammation, targeting Alzheimer's disease (AD) as initial clinical indication. The company's lead program is an antibody-based therapeutic, aiming to inhibit an innate immune response originating in the periphery which is triggered by AD pathology. The lead program is in late stage pre-clinical development, contemplating IND filing near-term. If successful in clinical development, the company's therapeutic strategy would represent a fundamental breakthrough for the AD field. MindImmune scientists are at the forefront in recognizing the therapeutic opportunities in targeting the immune system to treat brain disease. MindImmune is based in Kingston, RI and is building an affiliation with the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island to leverage the rapidly expanding Rhode Island ecosystem of academic neurosciences resources to advance its drug development programs.
1-888-653-2347 
support@leadiq.com 
